Price Chart

Profile

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
URL http://www.cadrenal.com
Investor Relations URL https://www.cadrenal.com/investors/
HQ State/Province Florida
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
URL http://www.cadrenal.com
Investor Relations URL https://www.cadrenal.com/investors/
HQ State/Province Florida
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A